EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
0.3401
-0.0158 (-4.44%)
Nov 6, 2026, 12:58 PM EST - Market open
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year. That makes EyePoint the 26,299th largest employer in the world and 3,343rd in the United States.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$13,028
Profits / Employee
-$1,432,911
Market Cap
29.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | 49 | 29.70% | 214 | 0 |
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| IRulya Therapeutics | 38 |
| Edesa Biotech | 17 |
| ProMIS Neurosciences | 11 |
| Dogwood Therapeutics | 8 |
| NanoViricides | 7 |
| Annovis Bio | 7 |
| Aldeyra Therapeutics | 6 |
EYPT News
- 6 hours ago - EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - GlobeNewsWire
- 1 day ago - EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026 - GlobeNewsWire
- 13 days ago - EyePoint downgraded to Hold from Buy at Jones - TheFly
- 17 days ago - EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PRNewsWire
- 17 days ago - EyePoint downgraded to Hold from Buy at Laidlaw - TheFly
- 17 days ago - EyePoint price target lowered to $1 from $5 at RBC Capital - TheFly
- 17 days ago - EyePoint downgraded to Neutral from Outperform at Mizuho - TheFly
- 17 days ago - EyePoint downgraded to Underweight from Neutral at JPMorgan - TheFly